Dimanche, 23 Septembre 2018
Latest news
Main » Trump Pitches Pharma Industry on Lowering Drug Prices

Trump Pitches Pharma Industry on Lowering Drug Prices

12 Mai 2018

Unfortunately, hiking drug prices in the rest of the world will have little effect on Americans' prescription costs, health policy experts say.

Another announced component of the Patients First Blueprint is the institution of incentives for lower list prices.

"Everyone involved in the broken system - the drug makers, insurance companies, distributors, pharmacy benefit managers, and many others - contribute to the problem", Trump said.

"Right now, we don't have a truly free market when it comes to drug pricing, and in too many cases, that's driving prices to unaffordable levels for some patients", Gottlieb said in a speech last week. "The middlemen became very, very rich".

However, although several of the administration's proposals will help lower costs, "We are concerned that some proposals would actually lead to higher costs for Americans, because they would weaken the ability of plans to negotiate lower prices". "Pharma finds a way to maximize profits". Drug maker Pfizer's shares rose 1.3 percent while Merck's stock increased 2.8 percent. One proposal, for example, could encourage drug makers to put prices in their ads, to promote ad-driven price competition.

Trump's Plan Includes Plenty of Steps He Can Take Without Congress: "It's framed as a pro-competitive agenda, and touches on a range of government programs that the administration can change through regulation - so that the president can take unilateral action", Daniel N. Mendelson, the president of research consultancy Avalere Health, told The New York Times. The administration's written proposal is more vague, saying that it "may" prohibit these gag clauses in plans for Part D, the Medicare drug program.

Some contracts between pharmacies and pharmacy benefit managers prohibit pharmacists from telling patients when a drug they need would be cheaper if they paid in cash, rather than using their insurance.

Use the federal government's bully pulpit to hold drugmakers accountable for large increases and highlight companies that didn't raise prices.

He was speaking as the Department of Health and Human Services released what it called a blueprint titled "American Patients First" with details of its plan to bring down drug costs. "If not, all of this other stuff seems like window dressing, important window dressing, but window dressing". It cuts $1.6 billion from the safety net and does nothing to reduce drug prices for seniors and the disabled.

Morbeck says she hopes his plan works. The speech came with a request for information, which means the policies will take some time to implement as the administration gathers feedback. As I pointed out in a previous column, 9 out of every 10 members of the U.S. House of Representatives, and a whopping 97 out of 100 senators have taken campaign contributions from pharmaceutical companies.

Health and Human Services Secretary Alex Azar, a former pharmaceutical company executive, said numerous actions the government was considering would not require approval by Congress and could take place through executive action within months. "It will happen, and it's going to happen quickly".

The drug industry's top lobbying arm, Pharmaceutical Research and Manufacturers of America, spent almost $26 million to sway federal decision makers previous year, according to records tallied by Center for Responsive Politics.

The president slammed pharmaceutical companies and their lobbyists as well as Obamacare and foreign countries for the rising prices of prescription drugs as he outlined his reforms. Health plans provide more favorable formulary placement in exchange for the rebates.

And the system for paying for the drugs dispensed under Medicare's Part B program also has to change, Azar added.

Trump Pitches Pharma Industry on Lowering Drug Prices